Belantamab Mafodotin, Pomalidomide, and Dexamethasone Show Promise in Triple-Class Exposed Multiple Myeloma
• A phase 1/2 trial evaluated belantamab mafodotin, pomalidomide, and dexamethasone (B-Pd) in patients with triple-class exposed relapsed/refractory multiple myeloma.
• The combination therapy demonstrated an overall response rate of 59% in heavily pretreated patients, indicating notable efficacy.
• The median progression-free survival was 11.5 months, suggesting a clinically meaningful benefit in this challenging patient population.
• Ocular toxicities, a known side effect of belantamab mafodotin, were managed with dose modifications and did not preclude continued treatment.
© Copyright 2025. All Rights Reserved by MedPath